The bidirectional cross-talk between the HER2 and the estrogen receptor pathways shapes biological differences in both molecular features and tumor microenvironment between hormone receptor (HR)-positive/HER2-positive and HR-negative/HER2-positive BC1–3. The gene discussed is ERBB2; the disease is neoplasm.